68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer

Clin Nucl Med. 2016 Sep;41(9):695-6. doi: 10.1097/RLU.0000000000001286.

Abstract

A 64-year-old man with prostate cancer and an increasing prostate-specific antigen (PSA) level under therapy with abiraterone acetate underwent a therapy with Ra. Before the first therapy and 4 weeks after the last cycle, the patient underwent Ga-PSMA PET, which showed a clear response of bone metastases.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Bone Neoplasms / radiotherapy*
  • Bone Neoplasms / secondary
  • Edetic Acid / analogs & derivatives
  • Gallium Isotopes
  • Gallium Radioisotopes
  • Humans
  • Male
  • Middle Aged
  • Oligopeptides
  • Organometallic Compounds
  • Positron-Emission Tomography / methods*
  • Prostate-Specific Antigen
  • Prostatic Neoplasms / pathology*
  • Radioisotopes / therapeutic use
  • Radium / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Gallium Isotopes
  • Gallium Radioisotopes
  • Oligopeptides
  • Organometallic Compounds
  • Radioisotopes
  • gallium 68 PSMA-11
  • Edetic Acid
  • Prostate-Specific Antigen
  • radium Ra 223 dichloride
  • Radium